Literature DB >> 24785096

Breast cancer prognosis predicted by nuclear receptor-coregulator networks.

Tram B Doan1, Natalie A Eriksson2, Dinny Graham1, John W Funder3, Evan R Simpson3, Elizabeth S Kuczek4, Colin Clyne3, Peter J Leedman5, Wayne D Tilley6, Peter J Fuller3, George E O Muscat7, Christine L Clarke8.   

Abstract

Although molecular signatures based on transcript expression in breast cancer samples have provided new insights into breast cancer classification and prognosis, there are acknowledged limitations in current signatures. To provide rational, pathway-based signatures of disrupted physiology in cancer tissues that may be relevant to prognosis, this study has directly quantitated changed gene expression, between normal breast and cancer tissue, as a basis for signature development. The nuclear receptor (NR) family of transcription factors, and their coregulators, are fundamental regulators of every aspect of metazoan life, and were rigorously quantified in normal breast tissues and ERα positive and ERα negative breast cancers. Coregulator expression was highly correlated with that of selected NR in normal breast, particularly from postmenopausal women. These associations were markedly decreased in breast cancer, and the expression of the majority of coregulators was down-regulated in cancer tissues compared with normal. While in cancer the loss of NR-coregulator associations observed in normal breast was common, a small number of NR (Rev-ERBβ, GR, NOR1, LRH-1 and PGR) acquired new associations with coregulators in cancer tissues. Elevated expression of these NR in cancers was associated with poorer outcome in large clinical cohorts, as well as suggesting the activation of ERα -related, but ERα-independent, pathways in ERα negative cancers. In addition, the combined expression of small numbers of NR and coregulators in breast cancer was identified as a signature predicting outcome in ERα negative breast cancer patients, not linked to proliferation and with predictive power superior to existing signatures containing many more genes. These findings highlight the power of predictive signatures derived from the quantitative determination of altered gene expression between normal breast and breast cancers. Taken together, the findings of this study identify networks of NR-coregulator associations active in normal breast but disrupted in breast cancer, and moreover provide evidence that signatures based on NR networks disrupted in cancer can provide important prognostic information in breast cancer patients.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast; Gene signature; Nuclear receptors; Prognosis; Transcriptome

Mesh:

Substances:

Year:  2014        PMID: 24785096      PMCID: PMC5528526          DOI: 10.1016/j.molonc.2014.03.017

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  28 in total

1.  SnapShot: NR coregulators.

Authors:  Neil J McKenna; Bert W O'Malley
Journal:  Cell       Date:  2010-10-01       Impact factor: 41.582

Review 2.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

3.  Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer.

Authors:  George E O Muscat; Natalie A Eriksson; Karen Byth; Sherene Loi; Dinny Graham; Shalini Jindal; Melissa J Davis; Colin Clyne; John W Funder; Evan R Simpson; Mark A Ragan; Elizabeth Kuczek; Peter J Fuller; Wayne D Tilley; Peter J Leedman; Christine L Clarke
Journal:  Mol Endocrinol       Date:  2013-01-04

4.  Breast cancer prognosis predicted by nuclear receptor-coregulator networks.

Authors:  Tram B Doan; Natalie A Eriksson; Dinny Graham; John W Funder; Evan R Simpson; Elizabeth S Kuczek; Colin Clyne; Peter J Leedman; Wayne D Tilley; Peter J Fuller; George E O Muscat; Christine L Clarke
Journal:  Mol Oncol       Date:  2014-04-04       Impact factor: 6.603

Review 5.  Molecular classification of estrogen receptor-positive/luminal breast cancers.

Authors:  Felipe C Geyer; Daniel N Rodrigues; Britta Weigelt; Jorge S Reis-Filho
Journal:  Adv Anat Pathol       Date:  2012-01       Impact factor: 3.875

6.  Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest.

Authors:  Meiling Lu; Toni Kwan; Chunjiang Yu; Feng Chen; Bethany Freedman; Jennifer M Schafer; Eun-Jig Lee; J Larry Jameson; V Craig Jordan; Vincent L Cryns
Journal:  J Biol Chem       Date:  2004-11-29       Impact factor: 5.157

7.  A comprehensive nuclear receptor network for breast cancer cells.

Authors:  Ralf Kittler; Jie Zhou; Sujun Hua; Lijia Ma; Yuwen Liu; Elisha Pendleton; Chao Cheng; Mark Gerstein; Kevin P White
Journal:  Cell Rep       Date:  2013-01-31       Impact factor: 9.423

Review 8.  Minireview: nuclear receptors and breast cancer.

Authors:  Suzanne D Conzen
Journal:  Mol Endocrinol       Date:  2008-04-16

9.  Prevalence and prognostic and predictive relevance of PRAME in breast cancer.

Authors:  Padraig Doolan; Martin Clynes; Susan Kennedy; Jai Prakash Mehta; John Crown; Lorraine O'Driscoll
Journal:  Breast Cancer Res Treat       Date:  2007-07-12       Impact factor: 4.872

Review 10.  Current and emerging biomarkers in breast cancer: prognosis and prediction.

Authors:  Marion T Weigel; Mitch Dowsett
Journal:  Endocr Relat Cancer       Date:  2010-09-23       Impact factor: 5.678

View more
  10 in total

1.  PRMT2 and RORγ expression are associated with breast cancer survival outcomes.

Authors:  Tae Gyu Oh; Peter Bailey; Eloise Dray; Aaron G Smith; Joel Goode; Natalie Eriksson; John W Funder; Peter J Fuller; Evan R Simpson; Wayne D Tilley; Peter J Leedman; Christine L Clarke; Sean Grimmond; Dennis H Dowhan; George E O Muscat
Journal:  Mol Endocrinol       Date:  2014-06-09

2.  Breast cancer prognosis predicted by nuclear receptor-coregulator networks.

Authors:  Tram B Doan; Natalie A Eriksson; Dinny Graham; John W Funder; Evan R Simpson; Elizabeth S Kuczek; Colin Clyne; Peter J Leedman; Wayne D Tilley; Peter J Fuller; George E O Muscat; Christine L Clarke
Journal:  Mol Oncol       Date:  2014-04-04       Impact factor: 6.603

3.  LRH-1 expression patterns in breast cancer tissues are associated with tumour aggressiveness.

Authors:  Jia-Min B Pang; Ramyar Molania; Ashwini Chand; Kevin Knower; Elena A Takano; David J Byrne; Thomas Mikeska; Ewan K A Millar; Cheok Soon Lee; Sandra A O'Toole; Colin Clyne; Kylie L Gorringe; Alexander Dobrovic; Stephen B Fox
Journal:  Oncotarget       Date:  2017-07-28

4.  NR1H3 Expression is a Prognostic Factor of Overall Survival for Patients with Muscle-Invasive Bladder Cancer.

Authors:  Junlong Wu; Fangning Wan; Haoyue Sheng; Guohai Shi; Yijun Shen; Guowen Lin; Bo Dai; Yiping Zhu; Dingwei Ye
Journal:  J Cancer       Date:  2017-03-07       Impact factor: 4.207

5.  Distinct Chemokine Receptor Expression Profiles in De Novo DLBCL, Transformed Follicular Lymphoma, Richter's Trans-Formed DLBCL and Germinal Center B-Cells.

Authors:  Barbara Uhl; Katharina T Prochazka; Katrin Pansy; Kerstin Wenzl; Johanna Strobl; Claudia Baumgartner; Marta M Szmyra; James E Waha; Axel Wolf; Peter V Tomazic; Elisabeth Steinbauer; Maria Steinwender; Sabine Friedl; Marc Weniger; Ralf Küppers; Martin Pichler; Hildegard T Greinix; Georg Stary; Alan G Ramsay; Benedetta Apollonio; Julia Feichtinger; Christine Beham-Schmid; Peter Neumeister; Alexander J Deutsch
Journal:  Int J Mol Sci       Date:  2022-07-17       Impact factor: 6.208

Review 6.  Insights into Orphan Nuclear Receptors as Prognostic Markers and Novel Therapeutic Targets for Breast Cancer.

Authors:  Reidun Aesoy; Colin D Clyne; Ashwini L Chand
Journal:  Front Endocrinol (Lausanne)       Date:  2015-08-07       Impact factor: 5.555

7.  The Nuclear Receptor, RORγ, Regulates Pathways Necessary for Breast Cancer Metastasis.

Authors:  Tae Gyu Oh; Shu-Ching M Wang; Bipul R Acharya; Joel M Goode; J Dinny Graham; Christine L Clarke; Alpha S Yap; George E O Muscat
Journal:  EBioMedicine       Date:  2016-02-18       Impact factor: 8.143

8.  LRH1 as a promising prognostic biomarker and predictor of metastasis in patients with non-small cell lung cancer.

Authors:  Yuechao Liu; Ying Xing; Hongmei Wang; Shi Yan; Xinzhu Wang; Li Cai
Journal:  Thorac Cancer       Date:  2018-10-01       Impact factor: 3.500

9.  Cytoplasmic and Nuclear Forms of Thyroid Hormone Receptor β1 Are Inversely Associated with Survival in Primary Breast Cancer.

Authors:  Wanting Shao; Christina Kuhn; Doris Mayr; Nina Ditsch; Magdalena Kailuweit; Verena Wolf; Nadia Harbeck; Sven Mahner; Udo Jeschke; Vincent Cavaillès; Sophie Sixou
Journal:  Int J Mol Sci       Date:  2020-01-03       Impact factor: 5.923

10.  A tumour suppressive relationship between mineralocorticoid and retinoic acid receptors activates a transcriptional program consistent with a reverse Warburg effect in breast cancer.

Authors:  Tram B Doan; Vanessa Cheung; Colin D Clyne; Heidi N Hilton; Natalie Eriksson; Morag J Young; John W Funder; George E O Muscat; Peter J Fuller; Christine L Clarke; J Dinny Graham
Journal:  Breast Cancer Res       Date:  2020-11-04       Impact factor: 6.466

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.